EVOQ Therapeutics
3 known investors
EVOQ Therapeutics develops immunotherapies for autoimmune diseases using its proprietary NanoDisc technology, which delivers disease-specific antigens to dendritic cells via subcutaneous administration to restore native immune tolerance. Its approach targets conditions such as Type 1 diabetes, Celiac disease, Multiple Sclerosis, and Lupus.
Investors · 3
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $761.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $287.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does EVOQ Therapeutics do?
- EVOQ Therapeutics develops immunotherapies for autoimmune diseases using its proprietary NanoDisc technology, which delivers disease-specific antigens to dendritic cells via subcutaneous administration to restore native immune tolerance. Its approach targets conditions such as Type 1 diabetes, Celiac disease, Multiple Sclerosis, and Lupus.
- Who are EVOQ Therapeutics's investors?
- EVOQ Therapeutics's investors include ID Ventures, Invest Michigan, Michigan Rise.